Compound Detail
CHEMBL3990014
MIRIKIZUMAB 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
No structure available
Basic Information
| ChEMBL ID | CHEMBL3990014 |
| Name | MIRIKIZUMAB |
| Phase | Approved |
| Structure Type | SEQ |
| Therapeutic | ✓ Yes |
0
Targets
0
Activities
0
Assay Types
0
PK Parameters
0
Publications
5
Known Names
5
Indications
1
Mechanisms
Drug Information
| Molecule Type | Antibody |
| First Approval | 2023 |
| Availability | Prescription |
| Chirality | Single Enantiomer |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| Interleukin-23 inhibitor | INHIBITOR | Interleukin-23 | ✓ | ✓ |
Indications
Colitis, Ulcerative Crohn Disease Immune System Diseases Inflammatory Bowel Diseases Psoriasis
ATC Classification
L04AC24
mirikizumab
Level 1: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Level 2: IMMUNOSUPPRESSANTS
Data from ChEMBL 36 via Core Engine